Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 4/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121485 | 1.00 | CNR2 (0.53) | CNR2STAT6TACR1ENPP2USP2 | |
| SCHEMBL4121005 | 0.92 | CNR2 (0.55) | CNR2STAT6WDR5 | |
| SCHEMBL4121009 | 0.92 | CNR2 (0.55) | CNR2STAT6WDR5 | |
| SCHEMBL4115433 | 0.91 | CNR2 (0.54) | CNR2STAT6EPHX2KDM4E | |
| SCHEMBL4115431 | 0.91 | CNR2 (0.54) | CNR2STAT6EPHX2KDM4E | |
| SCHEMBL4114702 | 0.90 | CNR2 (0.53) | CNR2ENPP2 | |
| SCHEMBL4114705 | 0.90 | CNR2 (0.53) | CNR2ENPP2 | |
| SCHEMBL4117052 | 0.90 | CNR2 (0.55) | CNR2STAT6TACR1 | |
| SCHEMBL4117055 | 0.90 | CNR2 (0.55) | CNR2STAT6TACR1 | |
| SCHEMBL1174080 | 0.89 | CNR2 (0.68) | CNR2TRPV4CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885STAT6 588/4885TACR1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.